Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.50 |
| ▸ | PNMT | P11086 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5503842 | 0.82 | IDO1 (0.46) | IDO1PNMTTAAR1CYP1A2CYP3A4 | |
| SCHEMBL29725299 | 0.82 | IDO1 (0.46) | IDO1PNMTTAAR1CYP1A2CYP3A4 | |
| SCHEMBL22444354 | 0.77 | IDO1 (0.42) | IDO1PNMTTAAR1CYP1A2CYP3A4 | |
| SCHEMBL13139886 | 0.76 | IDO1 (0.50) | IDO1PNMTTAAR1CYP1A2CYP3A4 | |
| SCHEMBL22195002 | 0.73 | KMT2A (0.36) | PKMLMNATSHRNPC1RAB9A | |
| SCHEMBL644724 | 0.72 | — | — | |
| SCHEMBL30123336 | 0.72 | — | — | |
| SCHEMBL3240698 | 0.72 | GRIN1 (0.43) | IDO1PNMTTAAR1CYP1A2CYP3A4 | |
| SCHEMBL15231529 | 0.71 | ALOX15 (0.41) | CYP3A4TSHRNPC1RAB9ASLC6A2 | |
| SCHEMBL778620 | 0.71 | TAAR1 (0.48) | IDO1TAAR1CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367871-B2 | Process for production of optically active sulfoxide compound using iron-salan complex catalyst | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-7776582-B2 | for gas chromatography; identifying an optically enhanced chiral ionic liquid (OCIL) for enantiomeric resolution | SIGMA-ALDRICH CO. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20100094037-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE SULFOXIDE COMPOUND USING IRON-SALAN COMPLEX CATALYST | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20090145197-A1 | Optically Enhanced Chiral Ionic Liquids | SIGMA-ALDRICH CO. NEWCO INC. | 2009-06-11 | — | — | US | disclosed |
| US-20060014955-A1 | Optically enhanced chiral ionic liquids | ADVANCED SEPARATION TECHNOLOGIES INC. (US) | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100094037-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE SULFOXIDE COMPOUND USING IRON-SALAN COMPLEX CATALYST | SCLY, SFXN1, SQOR | IDO1 358/4885PNMT 2458/4885TAAR1 3202/4885 |
| US-20060014955-A1 | Optically enhanced chiral ionic liquids | GCG, INF2, ELOVL3 | IDO1 737/4885PNMT 2412/4885TAAR1 1789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.